Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 1516407 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Search Results

Your Search for 'Angiogenesis Inhibitors - State-of-the-Science and Strategic Opportunities' returned 53 results - Page 1 of 3

  Sort by   
  Sorted by Rank Top-Bottom

Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report  
Global Industry Analysts, Inc., Feb 2011, Pages: 682
Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following


Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5791
Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of


Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5598
Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of


Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5557
Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies  
Bioseeker, May 2012, Pages: 6588
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and


Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides  
Bioseeker, May 2012, Pages: 5550
Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and


Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5967
Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas


Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5747
Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target


Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5700
Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target


Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 6261
Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and


Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5421
Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of


Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5482
Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target


Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors  
Bioseeker, May 2012, Pages: 5303
Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Angiogenesis, Cancer


Challenges and Opportunities in Developing Chemopreventive Agents  
Decision Resources, Inc., Nov 2007, Pages: 29
Chemopreventive Agent Development FDA-Approved Agents EGFR Inhibitors HMG-CoA Reductase Inhibitors Angiogenesis Inhibitors Matrix Metalloproteinases Combination Therapies Strategic Alliances with Nutraceutical


Histone Deacetylase inhibitors  
Lead Discovery, May 2005
key issues & conclusions - The field of HDAC inhibitors has been driven by their ability to modulate transcriptional activity. As a result, this therapeutic class is able to block angiogenesis and cell


The Complete Guide to Targeted Therapies in Oncology: A World Review  
Bioseeker, Dec 2006, Pages: 550
report - Understand the clinical and strategic challenges to the commercialization of aix major targeting strategies in oncology - Assess opportunities and risks for the continued development of targeting


U.S. Emerging Cancer Therapeutics Markets  
Frost & Sullivan, Jan 1999
and Development Pipeline - Market Engineering Research for the U.S. Market for Angiogenesis Inhibitors - Strategic Analysis and Forecasts of the Total Market - Competitive Structure


Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth  
Datamonitor, April 2010, Pages: 243
products -Identify licensing opportunities based on company portfolio and market needs Overview Catalyst Summary Executive Summary Strategic scoping and focus Datamonitor insight into the small


Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology  
Bioseeker, Oct 2006, Pages: 125
formulations, we identify that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer. Key reasons to read this report - Understand the clinical and strategic challenges to


The Targeted Cancer Therapies Pipeline: A Strategic Review  
Decision Resources, Inc., Dec 2009, Pages: 34
The Targeted Cancer Therapies Pipeline: A Strategic Review The current flurry of research into the development of new drugs against novel cancer targets is unprecedented. Many pharmaceutical and


Results:  First -   Prev -   1 -   2 -   3 -   Next -   Last


For enquiries please call us on:
  +353-1-415-1241 (GMT Office Hours)
  1-917-300-0470 (EST Office Hours)

   All rights reserved. © Copyright 2012 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network


Research and Markets RSS Feeds